Compare Crispr Therapeutics AG (CRSP) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Solaredge Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Solaredge Technologies Inc trades at $32.1 (market cap $2.05B). The key difference: Crispr Therapeutics AG is far larger — about 2.6× Solaredge Technologies Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | SEDG | |
|---|---|---|
Market Cap | $5.23B | $2.05B |
Sector | Health | Technology |
52-Week High | $76.78 | $78.51 |
52-Week Low | $44.34 | $25.10 |
Enterprise Value | $3.65B | $1.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
SolarEdge Technologies (SEDG) trades at $32.34, up 0.4% on the day, amid a challenging period marked by negative profitability and a bearish technical signal. Recent Q2 2026 earnings beat expectations with a surprise profit, but weak Q3 guidance and a net loss under GAAP accounting highlight ongoing struggles. The stock faces headwinds from soft U.S. residential demand and policy dependency, while European growth offers some offset. Analyst sentiment is mixed, with a consensus price target of $35.15 but a majority hold rating reflecting execution risks.
The outlook remains cautious due to persistent losses, high debt, and volatile cash flows. Investment opportunity hinges on margin recovery and policy support, but risks include competitive pressures, liquidity concerns, and macroeconomic sensitivity. Near-term performance will depend on Q3 results and U.S. market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
